Oraya Therapy for Wet AMD, Real World Clinical Outcomes
Results from the INTREPID study show that, in eyes with neovascular AMD, a single treatment of stereotactic radiotherapy with the Oraya Therapy can significantly reduce intravitreal injections over two years of follow-up while maintaining vision. Supplement includes authors Tim Jackson, PhD, FRCOphth; Frank Zimmerman, MD; Mahdy Ranjbar, MD; Katja Hatz, MD; and Christopher Brand, FRCOphth.
Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD uses low-energy, highly targeted X-rays to treat wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections. Full 2-year results from Oraya's INTREPID study were published in Ophthalmology, January 2015, and real world patient outcomes from three countries were present at EURETINA 15th Congress, September 2015. The Oraya Therapy is available in several treatment centres across Germany, Switzerland, and the United Kingdom.
http://www.orayainc.com/amd-clinical-outcomes/
